Skip to content

Dr. KAREN VAN ROY

Active
Private limited companyfounded 2019active for 7 yearsRavesteinstraat 48, 3191 Boortmeerbeek, BelgiumKBO/BCE: BE 0728.795.543
Summary

Dr. KAREN VAN ROY has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €71,550 and a net result of €21,093. Equity has been growing by about 6.9% per year since 2019. Its solvency ranks better than 72% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 24-06-2019 Normal situation
Activity
General medical practice NACE 86210
Establishment unit
2.291.034.288 3191 Boortmeerbeek, since 24-06-2019
Financial year end
31 December
Peppol
Reachable since 29-10-2024

Board and ownership

Board
  • Van Roy KarenDirector

Financial position

93 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Annual accounts 2025
Gross margin
€27,878
▼ 21.8%
Turnover
≈ €86,000
estimated
Profit
€21,093
▼ 32.1%
Equity
€71,550
▼ 7.7%
Total assets
€87,948
▼ 0.1%
Filed on 01-07-2026, 30 days before the deadline
Score breakdownraises riskLiquidity: current ratio 6.36, cash €2,668, halvedlowers riskSector: Human health activities (NACE 86)Figures for financial year 2025 (filed on 01-07-2026)Equity €71,550 (81.4% of total assets)Show the evidence

Checked score

Score 2025
93 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 48% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Strong
Solvency 100=
equity 81.4% of total assets
Liquidity 50-50
short-term debt 15.5% · cash 3.0%
Profitability 99-1
return on assets 24.0%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,160 companies, NACE 86, micro)
Last 24 months 12-2024: 0.1% 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.2%▲ +0.1 percentage points vs 05-2025 07-2025: 0.2%● unchanged vs 06-2025highest value 08-2025: < 0.1%▼ -0.2 percentage points vs 07-2025lowest value 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: 0.1%▲ +0.1 percentage points vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026 11-2026: 0.1%● unchanged vs 10-2026
Credit of up to €6,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 6.36 (13.75 in 2024), above the usual 1.5. Short-term debt is 15.5% and cash 3% of total assets. 18.6% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 23% on liquidity, 59% on profitability and 28% on growth.

The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Figures for financial year 2025 (filed on 01-07-2026)
NBB · annual accounts
raises risk · Liquidity: current ratio 6.36, cash €2,668, halved
NBB · annual accounts
lowers risk · Equity €71,550 (81.4% of total assets)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-07-2026, 30 days ahead of the deadline.
NBB · 7 filings
Deviation from the deadline
2025
30 days early
2024
7 days early
2023
33 days early
2022
38 days late
2021
16 days early
2020
1 day early
2019
39 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 1 day before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 15 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Recent changes

  1. · Gazette deed Incorporation
All 13 events

Comparable companies

These companies have the same main activity as Dr. KAREN VAN ROY: general medical practice (NACE 86210). They are comparable in size and age: total assets between €82,200 and €109,000, founded between 2018 and 2020.

CompanyTotal assetsGross margin
Dr. KAREN VAN ROY Boortmeerbeek€87,948€27,878
Dr. Lise Cornelis - Huisarts Gent€91,373€27,111
Hygie Liège€89,293€25,638
Dr. Pia Verhoeven, Huisarts Lochristi€82,186€27,539
DR. MACHTELD STORMS Rumst€109,292€29,641
Dr. Tessa Vande Velde Heist-op-den-Berg€106,697€32,155
Esculape Médicus Rixensart€98,877€23,652
Full comparison

Key facts about Dr. KAREN VAN ROY

What is the company number of Dr. KAREN VAN ROY?
The company number of Dr. KAREN VAN ROY is 0728.795.543. The VAT number is the same number with BE in front: BE 0728.795.543.
Where is Dr. KAREN VAN ROY based?
The registered office is at Ravesteinstraat 48, 3191 Boortmeerbeek.Company details
What does Dr. KAREN VAN ROY do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of Dr. KAREN VAN ROY?
The legal form of Dr. KAREN VAN ROY is Private limited company (BV).
When was Dr. KAREN VAN ROY founded?
Dr. KAREN VAN ROY was founded on 24-06-2019.
Is Dr. KAREN VAN ROY still active?
Yes, Dr. KAREN VAN ROY is an active enterprise in the KBO register.
What is the turnover of Dr. KAREN VAN ROY?
The turnover in financial year 2025 is ≈ €86,000. This figure is estimated from the gross margin of €27,878 and 47 comparable companies (NACE 86). It probably lies between €62,000 and €120,000.Financials
Is Dr. KAREN VAN ROY profitable?
In financial year 2025, Dr. KAREN VAN ROY made a profit of €21,093.
Where can I find the annual accounts of Dr. KAREN VAN ROY?
Dr. KAREN VAN ROY filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Dr. KAREN VAN ROY due?
Dr. KAREN VAN ROY must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.